David M Kent

发表

Three simple rules to ensure reasonably credible subgroup analyses

James F Burke, Jeremy B Sussman, David M Kent, 2015, BMJ : British Medical Journal.

The proposed 'concordance-statistic for benefit' provided a useful metric when modeling heterogeneous treatment effects.

Ewout W Steyerberg, Patrick W Serruys, David van Klaveren, 2018, Journal of clinical epidemiology.

Natural Language Processing for the Identification of Silent Brain Infarcts From Neuroimaging Reports

Yanshan Wang, Hongfang Liu, Sunyang Fu, 2019, JMIR medical informatics.

Against pragmatism: on efficacy, effectiveness and the real world

David M Kent, D. Kent, G. Kitsios, 2009, Trials.

Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network meta-analysis

Thomas A Trikalinos, Athina Tatsioni, David M Kent, 2009, The Lancet.

Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification.

David M Kent, Rodney A Hayward, D. Kent, 2007, JAMA.

Using group data to treat individuals: understanding heterogeneous treatment effects in the age of precision medicine and patient-centred evidence.

Issa J Dahabreh, David M Kent, D. Kent, 2016, International journal of epidemiology.

Multiple chronic conditions in type 2 diabetes mellitus: prevalence and consequences.

Joshua T. Cohen, Joshua T Cohen, David M Kent, 2015, The American journal of managed care.

Index event bias as an explanation for the paradoxes of recurrence risk research.

Issa J Dahabreh, David M Kent, D. Kent, 2011, JAMA.

Therapeutic innovations, diminishing returns, and control rate preservation.

Thomas A Trikalinos, David M Kent, T. Trikalinos, 2009, JAMA.

Prediction model for 30-day hospital readmissions among patients discharged receiving outpatient parenteral antibiotic therapy.

David M Kent, J. Paulus, D. Kent, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Extent of Early Ischemic Changes on Computed Tomography (CT) Before Thrombolysis: Prognostic Value of the Alberta Stroke Program Early CT Score in ECASS II

Michael D Hill, David M Kent, A. Demchuk, 2006, Stroke.

Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects

Ewout Steyerberg, David van Klaveren, David M Kent, 2018, British Medical Journal.

Baseline characteristics predict risk of progression and response to combined medical therapy for benign prostatic hyperplasia (BPH)

David M Kent, Jason Nelson, J. Nelson, 2015, BJU international.

Personalised medicine: not just in our genes

David M Kent, Georgios D Kitsios, D. Kent, 2012, BMJ : British Medical Journal.

New and Dis-Improved: On the Evaluation and Use of Less Effective, Less Expensive Medical Interventions

David M Kent, A Mark Fendrick, D. Kent, 2004, Medical decision making : an international journal of the Society for Medical Decision Making.

Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal

David M Kent, Rodney A Hayward, Doug G Altman, 2010, Trials.

Can the learning health care system be educated with observational data?

Issa J Dahabreh, David M Kent, D. Kent, 2014, JAMA.

Predicting mortality in incident dialysis patients: an analysis of the United Kingdom Renal Registry.

David M Kent, Christoph Wanner, D. Kent, 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Models with interactions overestimated heterogeneity of treatment effects and were prone to treatment mistargeting.

Ewout W Steyerberg, David van Klaveren, David M Kent, 2019, Journal of clinical epidemiology.

Improving diabetes prevention with benefit based tailored treatment: risk based reanalysis of Diabetes Prevention Program

Jeremy B Sussman, David M Kent, Rodney A Hayward, 2015, BMJ : British Medical Journal.

Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis

David M Kent, Rodney A Hayward, Sandeep Vijan, 2006, BMC medical research methodology.

Biases in Individualized Cost-effectiveness Analysis: Influence of Choices in Modeling Short-Term, Trial-Based, Mortality Risk Reduction and Post-Trial Life Expectancy

Ewout W Steyerberg, David van Klaveren, David M Kent, 2017, Medical decision making : an international journal of the Society for Medical Decision Making.

Risk and treatment effect heterogeneity: re-analysis of individual participant data from 32 large clinical trials.

Issa J Dahabreh, Douglas G Altman, David M Kent, 2016, International journal of epidemiology.